Dr. Masaru Miyagi is an Associate Professor in the Department of Pharmacology and Director of the Cancer Metabolism Shared Resource in Development of the Case Comprehensive Cancer Center.
We are motivated to develop analytical methods for proteome profiling and protein structural characterization. Mass spectrometry is the pre-eminent technology in analytical protein chemistry. However, current methods on the front end of mass spectrometry analysis are not fully utilizing the potential of modern mass spectrometry technologies. Development of advanced analytical methods on the front end of mass spectrometry analysis is, therefore, critical to advancing the study of proteins. We have characterized proteomes of various biological systems and developed useful mass spectrometry-based methodologies for protein/proteome analysis, which yielded > 90 peer-reviewed articles and six US patents, in the field of either proteomics or mass spectrometry. Our current research interests include developing an analytical method for identifying the targets of a drug and finding the signaling molecules secreted from microbes that promote/inhibit microbiome biofilm formation.
- U.S. Patent 6,194,190 (Issued February 27, 2001), titled “Amino-terminal deblocking enzyme”, Inventors: Yukiko Izu, Tetsuki Tanaka, Masaru Miyagi, Tetsuo Tanigawa, Jun Tomono, Susumu Tsunasawa, Ikunoshin Kato
- U.S. Patent 7,476,546 (Issued January 13, 2009), titled “Method for single oxygen atom incorporation into digested peptides using peptidases”, Inventors: Masaru Miyagi and K. C. Sekhar Rao
- U.S. Patent 8,580,534 (Issued November 12, 2013), titled “Method for incorporation of two oxygen atoms into digested peptides using peptidases”, Inventors: Masaru Miyagi
- U.S. Patent 8,921,515 B2 (Issued December 30, 2015), titled “Methods and compositions of preparation for proteome analysis”, Inventors: Masaru Miyagi and Chandra Sekhar Rao Kadiyala